Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1977 Jan;11(1):21–25. doi: 10.1128/aac.11.1.21

Therapy of Murine Aspergillosis with Amphotericin B in Combination with Rifampin or 5-Fluorocytosine

Julio Arroyo 1, Gerald Medoff *, George S Kobayashi 1
PMCID: PMC351911  PMID: 319750

Abstract

Suboptimal doses of amphotericin B in combination with either rifampin or 5-fluorocytosine were better than single-drug therapy in the treatment of disseminated Aspergillus fumigatus infection in mice. Despite the increased effectiveness of combination therapy, none of the therapeutic regimens we used completely eradicated infections in the mice when evaluated by mycological culture, even in long-term survivors.

Full text

PDF
21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassi L., Di Berardino L., Arioli V., Silvestri L. G., Lignière E. L. Conditions for immunosuppression by rifampicin. J Infect Dis. 1973 Dec;128(6):736–744. doi: 10.1093/infdis/128.6.736. [DOI] [PubMed] [Google Scholar]
  2. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  3. Block E. R., Bennett J. E. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med. 1973 Feb;142(2):476–480. doi: 10.3181/00379727-142-37049. [DOI] [PubMed] [Google Scholar]
  4. CHERNEW I., BRAUDE A. I. Depression of phagocytosis by solutes in concentrations found in the kidney and urine. J Clin Invest. 1962 Oct;41:1945–1953. doi: 10.1172/JCI104652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Corbel M. J., Eades S. M. Factors determining the susceptibility of mice to experimental phycomycosis. J Med Microbiol. 1975 Nov;8(4):551–564. doi: 10.1099/00222615-8-4-551. [DOI] [PubMed] [Google Scholar]
  6. GREEN W. R., BENNETT J. E., GOOS R. D. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. Arch Ophthalmol. 1965 Jun;73:769–775. doi: 10.1001/archopht.1965.00970030771004. [DOI] [PubMed] [Google Scholar]
  7. Kitahara M., Kobayashi G. S., Medoff G. Enhanced efficacy of amphotericin B and rifampicin combined in treatment of murine histoplasmosis and blastomycosis. J Infect Dis. 1976 Jun;133(6):663–668. doi: 10.1093/infdis/133.6.663. [DOI] [PubMed] [Google Scholar]
  8. Kitahara M., Seth V. K., Medoff G., Kobayashi G. S. Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus. Antimicrob Agents Chemother. 1976 Jun;9(6):915–919. doi: 10.1128/aac.9.6.915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kitahara M., Seth V. K., Medoff G., Kobayashi G. S. Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob Agents Chemother. 1976 Jun;9(6):908–914. doi: 10.1128/aac.9.6.908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kobbayashi G. S., Medoff G., Schlessinger D., Kwan C. N., Musser W. E. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science. 1972 Aug 25;177(4050):709–710. doi: 10.1126/science.177.4050.709. [DOI] [PubMed] [Google Scholar]
  11. Kwan C. N., Medoff G., Kobayashi G. S., Schlessinger D., Raskas H. J. Potentiation of the antifungal effects of antibiotics by amphotericin B. Antimicrob Agents Chemother. 1972 Aug;2(2):61–65. doi: 10.1128/aac.2.2.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Medoff G., Comfort M., Kobayashi G. S. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med. 1971 Nov;138(2):571–574. doi: 10.3181/00379727-138-35943. [DOI] [PubMed] [Google Scholar]
  13. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Titsworth E., Grunberg E. Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice. Antimicrob Agents Chemother. 1973 Sep;4(3):306–308. doi: 10.1128/aac.4.3.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Utz J. P., Garriques I. L., Sande M. A., Warner J. F., Mandell G. L., McGehee R. F., Duma R. J., Shadomy S. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis. 1975 Oct;132(4):368–373. doi: 10.1093/infdis/132.4.368. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES